Real-world effectiveness of extrafine single inhaler triple therapy (efSITT) via NEXThaler device on health status and sleep quality in Greek COPD Patients: Results from the CONFIDENCE study (ERS 2026) - May 30, 2026 - Abstract #PA341; Pres time: Sep 6, 2026; 08:00 AM - 09:30 AM; Location: PS-11; Board Number: 3; "Background: The efficacy of efSITT with beclometasone/formoterol/glycopyrronium (BDP/FF/G) in COPD has been demonstrated in randomized controlled trials and supported by real-world data, mainly for the pMDI formulation... These real-world data suggest significant improvements in health status and sleep quality in COPD patients, after switching to BDP/FF/G NEXThaler."
Clinical • Real-world • Real-world effectiveness • Real-world evidence • Asthma • Chronic Obstructive Pulmonary Disease • Immunology • Respiratory Diseases
|
|
K. Kostikas; P. Steiropoulos; K. Porpodis; E. Papapostolou; P. Efstathopoulos; S. Loukides
|